期刊
LEUKEMIA
卷 31, 期 1, 页码 136-142出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/leu.2016.229
关键词
-
资金
- NIH [CA05826]
- FDA [R01-002174]
- Celgene
- Millennium Pharmaceuticals
- Amyloidosis Research Fund
- Werner and Elaine Dannheiser Fund for Research on the Biology of Aging of the Lymphoma Foundation
- Memorial Sloan Kettering P30 NCI Cancer Center Support Grant (CCSG) [P30 CA008748]
- Thomas Israel Foundation
Stem cell transplantation (SCT), an effective therapy for amyloid light chain (AL) amyloidosis patients, is associated with low treatment-related mortality (TRM) with appropriate patient selection and risk-adapted dosing of melphalan (RA-SCT). Consolidation after SCT increases hematologic complete response (CR) rates and may improve overall survival (OS) for patients with
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据
分享论文
